Combining the Power of DEL With Industry-Leading E3 Ligase Expertise
Our DELigase platform, which enables our robust drug discovery pipeline, relies on two underlying features – our collection of E3 ligases and our DNA-encoded libraries of small molecules. Our platform is highly differentiated and allows us to identify small molecules that can either decrease or increase protein levels – processes we refer to as Targeted Protein Modulation.
The genome encodes over 600 E3 ligases, each one with a specific function. Currently, the field is largely focused on two E3 ligases, cereblon and VHL. We have enabled 60 E3 ligases in our drug discovery process. E3 ligases have historically been considered undruggable, but our knowledge of the structure and function of E3 ligases allowed us to create DNA-encoded libraries specifically designed to identify drugs that harness or inhibit E3 ligases.
DNA-Encoded Library (DEL)
Our DNA-encoded library is a large collection of more than five billion molecules, each tagged with a unique DNA bar code. The DEL is screened as a mixture to identify molecules that bind to a given protein target, and the DNA tag allows trace amounts of a molecule to be identified using DNA sequencing technologies. Nurix uses its DEL to find binders for both target proteins and E3 ligases, providing the key starting materials for its Targeted Protein Modulation process. There are several advantages of Nurix’s DELigase approach for drugging difficult targets such as ligases for the purpose of Targeted Protein Elevation and constructing Targeted Protein Degraders.